This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Stock Market News for Oct 30, 2024
by Zacks Equity Research
Wall Street ended mixed on Tuesday as U.S. job openings dropped to their lowest level in over three years.
Tenet (THC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Tenet (THC) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Tenet Healthcare (THC) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Tenet (THC) delivered earnings and revenue surprises of 25.75% and 1.48%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Stay Ahead of the Game With Tenet (THC) Q3 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Tenet (THC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
A Dose of Growth? Why Tenet Healthcare Could be a Buy Pre-Q3 Earnings
by Kaibalya Pravo Dey
THC's third-quarter results are likely to reflect growing patient admissions, utilization and patient days.
Are Investors Undervaluing Tenet Healthcare (THC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
HCA Healthcare (HCA) Beats Q3 Earnings Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of 1.61% and 0.04%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Investors Heavily Search Tenet Healthcare Corporation (THC): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Tenet (THC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Community Health Systems (CYH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Community Health Systems (CYH) delivered earnings and revenue surprises of -87.50% and 0.25%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Acadia Healthcare (ACHC) Q3 Earnings Expected to Decline
by Zacks Equity Research
Acadia Healthcare (ACHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tenet Healthcare (THC) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Tenet (THC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tenet Healthcare (THC) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
In the latest trading session, Tenet Healthcare (THC) closed at $163.87, marking a +1.34% move from the previous day.
Bargain or Bust? Decoding Tenet Healthcare Stock's Lower Valuation
by Kaibalya Pravo Dey
THC is well-positioned to benefit from the growing demand for hospital services. Yet, rising costs can potentially squeeze its margin growth.
Here's Why Tenet Healthcare (THC) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Tenet Healthcare (THC) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
In the latest trading session, Tenet Healthcare (THC) closed at $161.71, marking a -1.41% move from the previous day.
Here's Why Tenet Healthcare (THC) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Tenet Healthcare (THC) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Tenet Healthcare (THC) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Tenet Healthcare (THC) closed at $155.82 in the latest trading session, marking a +1.99% move from the prior day.
Brookdale Q3 2024 Occupancy Jumps, Logs 35th Straight Monthly Boost
by Zacks Equity Research
BKD's weighted average occupancy for September grows 30 bps sequentially.
Tenet Healthcare (THC) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
In the closing of the recent trading day, Tenet Healthcare (THC) stood at $152.78, denoting a -0.84% change from the preceding trading day.
Community Health Teams Up With Denim to Scale Conversational AI
by Zacks Equity Research
With this move, CYH intends to streamline agent workload, which can result in more savings for the company.
Here is What to Know Beyond Why Tenet Healthcare Corporation (THC) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Tenet (THC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Does Universal Health's Low P/E Ratio Signal a Suitable Entry Point?
by Debasmita Chatterjee
UHS rides on increased patient volumes. It can effectively cater to its patients through its extensive treatment network.
Merit Medical Stock Gains 24.7% Year to Date: What's Behind the Rally?
by Zacks Equity Research
MMSI shows strong growth momentum with a robust product portfolio and recent acquisitions, positioning itself well in competitive healthcare markets.
Trinity Biotech Shares Surge on Positive Pre-Pivotal Clinical CGM Trial
by Zacks Equity Research
TRIB announces positive results from its pre-pivotal clinical European trial for a next-gen continuous glucose monitor, setting the stage for further development in 2025.